Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02751528 · ClinicalTrials.gov registry record · Phase 1
QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
A Phase 1 study, sponsored by NantBioScience.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02751528 is a Phase 1 study that was terminated before completion, run by NantBioScience. The registered enrollment target is 3 participants.
The verdict
NCT02751528, a Phase 1 study, was terminated before completion, sponsored by NantBioScience.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ETBX-021 is safe and effective in the treatment of unresectable locally advanced or metastatic HER2-low-expressing breast cancer.
Interventions
- BIOLOGICAL ETBX-021
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-03-04 |
| Est. Completion | 2018-08-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02751528
The ClinicalTrials.gov registry entry for NCT02751528 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NantBioScience, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ETBX-021 is the first listed.
NCT02751528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02751528 about?
NCT02751528 is a clinical study titled "QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer". The purpose of this study is to determine whether ETBX-021 is safe and effective in the treatment of unresectable locally advanced or metastatic HER2-low-expressing breast cancer.
What is the current status of trial NCT02751528?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-03-04. Estimated completion is 2018-08-16.
What interventions are being tested in trial NCT02751528?
The interventions under investigation include: ETBX-021 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02751528?
This trial is sponsored by NantBioScience, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.